[Regression of a choroidal metastasis from prostate adenocarcinoma after hormonal therapy].
METHODS
We report a case of a patient diagnosed with prostatic adenocarcinoma with multiple bone metastases and a choroidal metastasis in his left eye. Hormonal therapy with an anti-androgen and a LH-RH agonist was followed by regression of the choroidal mass over a period of 2 months. No metastatic recurrence has been demonstrated after a follow-up period of 14 months.


CONCLUSIONS
Complete resolution of choroidal metastases of prostatic adenocarcinoma with hormonal therapy is exceptional, but the effect of this treatment on such metastases should be observed before recommending radiation therapy.
Barbón
J J
JJ
Hospital San Agustín de Avilés, Asturias, Spain. jjbarbon@telecable.es
González-Tuero
J
J
Gay
L L
LL
Pérez-García
F J
FJ
Sampedro
A
A
D000230:Adenocarcinoma / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology / Q000556:secondary*; D000368:Aged; D000726:Androgen Antagonists / Q000627:therapeutic use*; D000813:Anilides / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D001706:Biopsy; D001859:Bone Neoplasms / Q000556:secondary; D002830:Choroid Neoplasms / Q000175:diagnosis / Q000556:secondary*; D005500:Follow-Up Studies; D006801:Humans; D008279:Magnetic Resonance Imaging; D008297:Male; D009570:Nitriles / Q000627:therapeutic use*; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D013997:Time Factors; D014105:Tosyl Compounds / Q000627:therapeutic use*; D016896:Treatment Outcome
D000726:Androgen Antagonists; D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen